Related Experiment Videos
A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B
T Kagawa1, T Morizane, H Saito
1Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
The American Journal of Gastroenterology
|February 1, 1993
Summary
Weekly interferon-beta therapy for chronic hepatitis B patients led to significant reductions in viral DNA polymerase and improved liver enzyme levels. This treatment also showed promise in achieving HBeAg seroconversion and normalizing alanine aminotransferase levels post-therapy.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B (CHB) remains a significant global health concern.
- Hepatitis B e-antigen (HBeAg) positivity indicates active viral replication and infectivity.
- Current treatments aim to suppress viral replication and induce seroconversion.
Purpose of the Study:
- To evaluate the efficacy of weekly interferon-beta therapy in patients with chronic hepatitis B.
- To assess the impact of interferon-beta on viral markers and liver enzymes.
- To determine the rate of HBeAg seroconversion and normalization of alanine aminotransferase (ALT) levels.
Main Methods:
- Ten HBsAg and HBeAg positive CHB patients received 3 million units of interferon-beta intravenously weekly for 24 weeks.
- Patients were monitored for 6 months post-therapy.
- Serum hepatitis B virus (HBV)-DNA polymerase activity, HBeAg/anti-HBe status, and ALT levels were assessed.
Main Results:
- Significant reductions in HBV-DNA polymerase activity and ALT levels were observed during and after therapy.
- Five out of ten patients achieved HBeAg to anti-HBe seroconversion by 6 months post-therapy.
- Four of these five patients also normalized their serum ALT levels.
Conclusions:
- Weekly interferon-beta administration is effective in reducing viral activity and improving liver function in CHB patients.
- The treatment demonstrates potential for inducing HBeAg seroconversion and normalizing ALT levels.
- Interferon-beta offers a viable therapeutic option for managing chronic hepatitis B.